Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,895
Total Claims
$1.6M
Drug Cost
641
Beneficiaries
$2,508
Cost/Patient
Risk Score Breakdown 6/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+135%
Cost per patient vs peers
$2,508 vs $1,068 avg
+85%
Brand preference vs peers
16.6% vs 9.0% avg
Brand vs Generic
Brand: 1,776 claims · $1.4M
Generic: 8,907 claims · $236K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phosphate | 152 | $167K |
| Linagliptin | 145 | $163K |
| Empagliflozin | 108 | $151K |
| Dapagliflozin Propanediol | 105 | $149K |
| Insulin Glargine,hum.Rec.Anlog | 109 | $79K |
| Apixaban | 67 | $71K |
| Insulin Glargine,hum.Rec.Anlog | 99 | $61K |
| Insulin Aspart | 61 | $53K |
| Budesonide/Formoterol Fumarate | 105 | $49K |
| Semaglutide | 46 | $47K |
| Lipase/Protease/Amylase | 12 | $36K |
| Dulaglutide | 18 | $32K |
| Atorvastatin Calcium | 1,280 | $32K |
| Insulin Nph Hum/Reg Insulin Hm | 22 | $30K |
| Rivaroxaban | 25 | $29K |
Prescribing Profile
Patient Profile
71
Avg Age
51%
Female
1.21
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data